Social Risk Factors and Discrimination in Cancer Survivorship
Launched by MEDSTAR HEALTH RESEARCH INSTITUTE · Mar 18, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding and improving the health and well-being of Black cancer survivors, specifically those who have had breast or prostate cancer. The study aims to identify social factors that may affect their recovery and access to care, and to connect them with community resources that can provide support. Researchers will explore how having Community Health Workers—individuals who help guide patients through the healthcare system—can enhance the quality of life and social connections for these survivors. Additionally, the trial will assess how training healthcare staff in anti-racism practices might reduce experiences of discrimination among patients.
To be eligible for the trial, participants need to be Black or African American and have been diagnosed with either stage I-III breast or prostate cancer, with their treatment completed, or stage IV cancer diagnosed about six months ago. Participants can expect to engage with community resources and provide feedback on their experiences, which will help improve healthcare for future cancer survivors. This study is currently recruiting individuals aged 65 to 74, and it welcomes all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of stage I-III breast or prostate cancer and completed curative treatment (surgery, radiation, chemotherapy) or finalized treatment plan (e.g. watch and wait); OR Stage IV breast or prostate cancer approximately 6 months from diagnosis
- • Black or African American race
About Medstar Health Research Institute
MedStar Health Research Institute (MHRI) is a leading clinical research organization affiliated with MedStar Health, dedicated to advancing medical knowledge and improving patient care through innovative research initiatives. With a robust portfolio of clinical trials across various therapeutic areas, MHRI collaborates with healthcare professionals, academic institutions, and industry partners to facilitate the development of new treatments and interventions. The institute is committed to maintaining the highest standards of ethical conduct and scientific rigor while fostering a culture of inquiry that enhances the health and well-being of the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Patients applied
Trial Officials
Hannah Arem, PhD
Principal Investigator
Medstar Health Research Institute
Mandi Pratt-Chapman, PhD
Principal Investigator
George Washington University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials